nerandomilast

News

Boehringer bags FDA okay for new pulmonary fibrosis drug

Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?

News

Boehringer eyes H2 drug launches after strong H1 growth

Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025,

News

Boehringer drug scores in another pulmonary fibrosis trial

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.

News

Trial sets up filings for Boehringer IPF drug nerandomilast

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O

Boehringer bags FDA okay for new pulmonary fibrosis drug

Boehringer eyes H2 drug launches after strong H1 growth

Boehringer drug scores in another pulmonary fibrosis trial

Trial sets up filings for Boehringer IPF drug nerandomilast

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

nerandomilast

Editor's Picks